StockNews.AI
UG
StockNews.AI
11 days

United-Guardian Reports Second Quarter Results

1. UG's Q2 net sales dropped to $2.84M, down from $3.39M in 2024. 2. Net income fell to $626,826, a decrease from $956,225 in Q2 2024. 3. Sales of pharmaceuticals and lubricants increased, but cosmetics decreased. 4. Softer demand in Asia led to reduced purchases by ASI, UG's major distributor. 5. UG aims to boost Renacidin sales by including it in more drug formularies.

6m saved
Insight
Article

FAQ

Why Bearish?

A decrease in sales and income suggests weak performance. Historical precedent shows similar downturns impact stock prices negatively.

How important is it?

The reported financial decline directly affects UG's market perception and could influence trading decisions.

Why Short Term?

Immediate sales declines impact investor confidence. Recovery in cosmetic sales could revitalize shares if projected improvements occur.

Related Companies

ASHPGKMB
August 08, 2025 09:00 ET  | Source: United-Guardian, Inc. HAUPPAUGE, N.Y., Aug. 08, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2025. Second quarter net sales decreased from $3,390,205 in 2024 to $2,838,225 in 2025, with net income decreasing from $956,225 ($0.21 per share) to $626,826 ($0.14 per share). As compared with the first quarter of 2025, the second quarter net sales increased by 14% and net income increased by 12%. Net sales for the six-month period ended June 30th decreased from $6,645,149 in 2024 to $5,319,352 in 2025 and net income decreased from $1,881,667 ($0.41 per share) to $1,187,721 ($0.26 per share). Donna Vigilante, President of United-Guardian, stated, “Sales of our pharmaceuticals and medical lubricants both increased for the first half of 2025 compared with the same period in 2024. Sales of our medical lubricants increased by 12% and pharmaceutical product sales increased by 11% in the first six months of 2025 compared with the same period in 2024. Those increases were offset by a decrease of sales of our cosmetic ingredients in the first six months of 2025 compared with the same period in 2024. This decrease was attributable to reduced purchases by Ashland Specialty Ingredients (“ASI”), our largest cosmetic distributor. The primary reason for the decrease in purchases by ASI was softer demand in Asia, which resulted in an inventory overstock situation that ASI had to work down before it could increase its purchases. We are working closely with ASI and are hopeful that cosmetic sales will improve in the second half of the year as this overstock situation is resolved. We are also initiating a new project to have Renacidin®, our most important pharmaceutical product, included in additional drug formularies. If this project is successful, we should be able to significantly increase sales of Renacidin over the coming years.” United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.  Financial Results for theThree and Six Months EndedJune 30, 2025 and 2024 STATEMENTS OF INCOME (unaudited)  THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,  2025  2024  2025  2024              Net sales$2,838,225 $3,390,205 $5,319,352 $6,645,149 Costs and expenses:            Cost of sales 1,340,854  1,561,090  2,463,930  3,117,580 Operating expenses 694,050  602,777  1,326,785  1,171,642 Research and development expense    107,868   111,660   222,262   214,642 Total costs and expenses 2,142,772  2,275,527  4,012,977  4,503,864  Income from operations  695,453  1,114,678  1,306,375  2,141,285 Other income (expense):            Investment income 70,573  100,007  155,260  198,080 Net gain (loss) on marketable securities  24,576   (9,501)  36,926   31,995 Total other income  95,149   90,506   192,186   230,075  Income before provision for income taxes 790,602  1,205,184  1,498,561  2,371,360 Provision for income taxes  163,776   248,959   310,840   489,693  Net income$ 626,826 $ 956,225 $1,187,721 $1,881,667 Earnings per common share (basic and diluted)$ 0.14  $ 0.21  $          0.26  $          0.41  Weighted average shares (basic and diluted) 4,594,319  4,594,319  4,594,319  4,594,319              

Related News